1 completed, 1 not yet recruiting, 1 recruiting. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Gynecological Malignancies: new trials by email Literature Review of Gynecological Malignancies trials Research Report on Gynecological Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors 9MW2821+other anticancer therapy - Gynecological Malignancies | Phase 1 / Phase 2 | Not yet recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 260 | 2025-04-15 | 2025-04-15 |
| A Study of BL-M07D1 in Patients With Recurrent or Metastatic Gynecologic Malignancies BL-M07D1 - Gynecological Malignancies | Phase 1 / Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 158 | 2024-02-29 | 2026-10-23 |
| AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR A1: AMG 386 10 mg/kg + Liposomal doxorubicin, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan - Cancer, Carcinoma | Phase 1 | Completed | Amgen | 103 | 2009-01-01 | 2015-09-29 |
Carcinoma (1) · Fallopian Tube Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Ovarian Neoplasms (1)
Adnexal Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gonadal Disorders (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Neoplastic Processes (1) · Ovarian Diseases (1)
Topotecan (1) · liposomal doxorubicin (1) · trebananib (1)
Amgen (1) · Mabwell (Shanghai) Bioscience Co., Ltd. (1) · Sichuan Baili Pharmaceutical Co., Ltd. (1)
China (2) · Australia (1) · Belgium (1) · United States (1)
Hanmei Lou, Professor (1) · Lingying Wu, PHD (1)